Fundraising Projectsto achieve even more

We Currently Need Funds For The Following Research Areas

Wound healing:

Dermal paste for non-healing wounds – We have developed a bioactive dermal paste to replace the traditionally available “sheets”, which do not work well for complex wounds. This paste has the potential to integrate more closely with the wound bed and provide the structural framework for skin regeneration. This has potential applications across many areas including non-healing diabetic ulcers and wounds in people who would not tolerate the process of more traditional skin grafts. The technology could impact internal wounds such as anal fissures, which cause misery and distress to many people, and address poorly understood conditions such as gastroesophageal reflux disease (GERD).

Dermal hydrogel – For use in rapid healing of serious burns with easy application of a semi-solid gel that can be applied directly to a burn and “fixed” with a UV light, creating a dressing with the ability to regenerate skin whilst protecting the wounds.

Intestinal disorders:

We are aiming for two areas of potential benefit to people living with Intestinal Bowel Disease (IBD):

Translational Research: There is a clinical need to reconstruct bowel tissue whereby underlying illness has resulted in poor healing. This is the case in long-standing inflammatory diseases and/or bowel cancer. Generating tissue engineered short segments of bowel will allow the behaviour tissue to be analysed in a controlled environment to allow production and assessment of the best scaffold and best cell source to re-popularise it. This essentially could pave the way to scale up to larger segments of bowel that ultimately will lead to the future goal of tissue replacement.

Better drug treatment options for patients living with IBD: Our model could also be applied to regenerate human tissue to improve medications, such as immunotherapy by increasing efficacy and minimising side effects. We collect healthy intestinal cells from the patients and culture them as ‘mini-guts’ in the laboratory, with the aim of studying the disease and also develop other treatments with more targeted action that can provide personalised benefit to patients. This model could allow novel treatments to be trialled without risk to patients, and minimising animal use for drug screening.

 Mechanisms for testing new drugs for liver disease:

 A major limitation to the development of safe drugs to treat liver disease is the use of appropriate pre-clinical testing tools. Our aim is to use a biological tissue engineering approach to produce bio-engineered ‘mini-livers’ capable of replicating physiological function, which would enable the testing of new drugs on fully functional mini-tissues created in the laboratory, reducing costly and extensive tests in animals.

We are very grateful for your consideration of our projects, we think that this will provide the opportunity to partner with us and be involved with innovative approaches to serious issues within the Health System. Those research approaches not only have the potential to help saving a huge amount of money for the NHS but more importantly, have very positive impact on the lives of those in need.